119 related articles for article (PubMed ID: 14991533)
1. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients.
Hashiguchi Y; Tsuda H; Inoue T; Nishimura S; Suzuki T; Kawamura N
Hum Pathol; 2004 Feb; 35(2):165-75. PubMed ID: 14991533
[TBL] [Abstract][Full Text] [Related]
2. Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins.
Tachibana M; Watanabe J; Matsushima Y; Nishida K; Kobayashi Y; Fujimura M; Shiromizu K
Int J Gynecol Cancer; 2003; 13(5):598-606. PubMed ID: 14675342
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of p53 and RB pathways in epithelial ovarian cancer.
Hashiguchi Y; Tsuda H; Yamamoto K; Inoue T; Ishiko O; Ogita S
Hum Pathol; 2001 Sep; 32(9):988-96. PubMed ID: 11567230
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
5. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma.
Jayasurya R; Francis G; Kannan S; Lekshminarayanan K; Nalinakumari KR; Abraham T; Abraham EK; Nair MK
Int J Cancer; 2004 May; 109(5):710-6. PubMed ID: 14999779
[TBL] [Abstract][Full Text] [Related]
6. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
[TBL] [Abstract][Full Text] [Related]
7. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
8. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer.
Kusume T; Tsuda H; Kawabata M; Inoue T; Umesaki N; Suzuki T; Yamamoto K
Clin Cancer Res; 1999 Dec; 5(12):4152-7. PubMed ID: 10632354
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
10. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
11. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
12. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma.
Naka T; Toyota N; Kaneko T; Kaibara N
Anticancer Res; 1998; 18(1B):555-64. PubMed ID: 9568177
[TBL] [Abstract][Full Text] [Related]
13. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression.
Peiró G; Diebold J; Löhrs U
Am J Clin Pathol; 2002 Dec; 118(6):922-9. PubMed ID: 12472286
[TBL] [Abstract][Full Text] [Related]
14. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma.
Kang YK; Kim WH; Jang JJ
Hum Pathol; 2002 Sep; 33(9):877-83. PubMed ID: 12378511
[TBL] [Abstract][Full Text] [Related]
15. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
16. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas.
Bai M; Tsanou E; Skyrlas A; Sainis I; Agnantis N; Kanavaros P
Anticancer Res; 2007; 27(4B):2345-52. PubMed ID: 17695524
[TBL] [Abstract][Full Text] [Related]
18. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
